Products Lurbinectedin
Lurbinectedin Phase 1/2 Recruiting 💤 Quiet Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
May 23, 2023 → Apr 20, 2028
About Lurbinectedin Lurbinectedin is a phase 1/2 stage product being developed by Jazz Pharmaceuticals for Refractory Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05734066. Target conditions include Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma.
Clinical Trials (6) NCT ID Phase Status Start Completion Indication NCT04291937 Pre-clinical Completed — — Small Cell Lung Cancer NCT06217536 Phase 1/2 Withdrawn Oct 31, 2024 Oct 31, 2027 Locally Advanced Soft Tissue Sarcoma NCT05918640 Phase 1/2 Recruiting Jul 27, 2023 Jul 30, 2028 Ewing Sarcoma NCT05734066 Phase 1/2 Recruiting May 23, 2023 Apr 20, 2028 Refractory Ewing Sarcoma NCT05244239 Phase 1 Recruiting Jul 27, 2022 Jul 28, 2027 Extensive Stage Lung Small Cell Carcinoma NCT05126433 Phase 2 Terminated Mar 3, 2022 Dec 20, 2023 Advanced Solid Tumor
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 Eribulin mesilate + Irinotecan hydrochloride Eisai Phase 1/2 perampanel Eisai Phase 2 rabeprazole sodium Eisai Pre-clinical Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Rufinamide Eisai Phase 3
Other Products from Jazz Pharmaceuticals